Springer Nature
Browse
40164_2019_153_MOESM2_ESM.pdf (409.14 kB)

MOESM2 of A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma

Download (409.14 kB)
journal contribution
posted on 2019-11-16, 05:19 authored by Shanshan Zhang, Zhaojian Gong, Peter Oladimeji, Duane Currier, Qipan Deng, Ming Liu, Taosheng Chen, Yong Li
Additional file 2: Figure S1. Compound activity and plate Z′-factor for the primary screening. (A) Compound activity distribution. Blue dots (Inhibitor Control): positive control group (10 μM staurosporine, 100% inhibition); black dots (Neutral Control): negative control group (DMSO group, 0% inhibition); yellow dots (Hit Compound): primary hits (hit compound) (125 compounds that displayed ≥ 90% inhibition chosen for a dose-response analysis); grey dots (Compound): compounds not chosen for further confirmation (% inhibition < 90%). Y-axis: % Activity is assessed as the percentage of viability inhibited. The activity from 12,800 library compounds and control compounds in each plate were shown. (B) Z′-factor calculated for each plate. (C) The dose response curves for cell viability of Daoy cells. Ten concentrations, 1:3 serially diluted ranging from 50 to 0.0025 μM, were used in triplicate.

Funding

Office of Extramural Research, National Institutes of Health

History